The week was fairly quiet as US equities finished higher on Friday, 4/1/11 the 1st day of Q2. Markets opened up and rose through the week. Although significant macro risk remains, markets seem to be largely dismissing possible negatives and continue to creep higher. Headlines from the Middle East and Japan were moderate in nature in relation to the recent past.
At the end of the week, the NASDAQ was up 8.53 (0.31%) to 2789.60 versus last weeks (3/25/11) end of week close of 2743.06 which had been up 0.24%, still higher. Visibility with elements of conviction continues to be the indicators of momentum initiatives … (Last week close (3/25/11) =LW)
- Advanced Cell Technology (OTC: ACTC) up $0.009 (4.92%) to $0.192 (LW $0.167);
- Athersys (NASDAQ:ATHX) up $0.02 (0.70%) to $2.86 (LW $2.50);
- Cytori Therapeutics (NASDAQ:CYTX) up $0.09 (1.15%) to $7.91 (LW $7.57);
- Aastrom Bioscience (ASTM) up $0.04 (1.60%) to $2.54 (LW $2.21);
- BioMimetic (NASDAQ:BMTI) up $0.31 (2.36%) to $13.42 (LW $12.44);
- Opexa (OPXA) up $0.06 (3.59%) $1.73(LW $1.71)
- BioTime (AMEX: BTX) up $0.12 (1.61%) to $7.57 (LW $7.54);
- ThermoGenesis (NASDAQ:KOOL) up 0.10 (4.78%) to $2.19 (LW $2.00);
- Geron (NASDAQ:GERN) up $0.08 (1.58%) to $5.13 (LW $4.83);
- StemCells (STEM) up $0.01 (1.10%) to $0.92 (LW $0.857);
- Neuralstem (AMEX:CUR) up 0.02 (1.11%) to $1.82 (LW $1.81); and
- ReNeuron Group (RENE.L) up $0.01 (0.19%) to $5.81 (LW $5.90).
- Osiris (OSIR down -$ 0.02 (-0.28%) to $7.24 (LW $6.94);
- International Stem Cell (OTCQB:ISCO) down $0.04 (-$0.2.99%) to $1.30 (LW $1.40);
- Pluristem (NASDAQ:PSTI) down -$0.01 (-0.23%) to $2.58 (LW $2.48);
- Tengion (TNGN) down -$0.03 (-1.18%) to $2.52 (LW $2.65);
- ImmunoCellar Therapeutics (NYSEMKT:IMUC) down $0.05 (-2.17) to $2.25 (LW $2.30); and
- Brainstorm (NASDAQ:BCLI) down $0.005 (-1.67%) at $0.295 (LW $0.30).
- NeoStem (AMEX: NBS) flat at $1.72 (LW $1.65); and
- BioHeart (OTCPK:BHRT) flat at $0.19 (LW $0.19).
The Bottom Line: From the 4/1/11 close, the continued volatility in the markets is adjusting investors’ attitudes, as can be seen by the numbers (last week 4/1 versus 3/25). Advancing stocks (12 to 6) outpaced those declining, a better indicator (versus 3/25’s close of 9 advancers versus 8 decliners). The regenerative medicine universe continues to gyrate during periods of market unrest. The big winner for week ending 4/1/11 was BioMimetic (BMTI) up $0.31 (2.36%). Last week’s news flow highlighted: clinical trials advance military burn care, NeoStem’s (AMEX: NBS) FY10 earnings (13%) jump, rising concerns about induced pluripotent (iPS) cells, Stem Cell Therapeutics (TSX: V: SSS) unit financing closing, Mesoblast’s answer to Valeant (TSE: VRX) proposal to Cephalon (NASDAQ:CEPH), radiation exposure issues in Japan, ThermoGenesis (KOOL) cord blood adaptation in China, Japan’s beginning a stem cell collection strategy, StemCells (STEM) adding again to its revenue portfolio, International Stem Cell’s (OTCQB:ISCO) FY10 results, Tengion’s (TNGN) Q4/10 and FY10 results, Cellerant Therapeutics (PVT) initiation of a PI/II clinical trial for leukemia and a potential of a cell based therapy for protection of acute radiation. The year is still young and the rambunctious 1st quarter is now history. Hopefully, the regenerative medicine universe continues to trade into a cyclical correlation! But, hesitancy is being nudged by volume indicators. Reiterating, short sale ratio data continues to carry significance. One side indicator is US small-cap mutual funds attracted bigger inflows. More news should stimulate visibility but, as I said last week, who has been watching? No, Jedi knight but, “live and breathe the force” as visibility “slinks” back into the market.